HanAll Biopharma Reports Second Quarter 2022 Results and Pro

/PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company focusing on delivering breakthrough therapies for patients, reported...

Related Keywords

China , Seoul , Soult Ukpyolsi , South Korea , Japan , Sean Jeong , Hanall Biopharma , Prnewswire Hanall Biopharma , Pipeline Development , Hanall Biopharma Co Ltd , Major Development , All Biopharma , Development Highlights , Project Code , Harbour Biomed , Biologics License Application , Daewoong Pharmaceutical , Biotechnology , Health Care Amp Hospitals , Pharmaceuticals , Medical Pharmaceuticals , Banking Amp Financial Services , Earnings ,